President Joe Biden's administration's drug-price negotiation law is facing a resistance from Johnson & Johnson, with its Chief Executive Officer Joaquin Duato saying that the law poses a threat to new product development and to fewer medicines in the future.
"The number of medicines that will be there will be less," Duato said in an interview with Bloomberg Chief Future Officer, Bloomberg reported.
